Your browser doesn't support javascript.
loading
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
Macauda, Angelica; Clay-Gilmour, Alyssa; Hielscher, Thomas; Hildebrandt, Michelle A T; Kruszewski, Marcin; Orlowski, Robert Z; Kumar, Shaji K; Ziv, Elad; Orciuolo, Enrico; Brown, Elizabeth E; Försti, Asta; Waller, Rosalie G; Machiela, Mitchell J; Chanock, Stephen J; Camp, Nicola J; Rymko, Marcin; Razny, Malgorzata; Cozen, Wendy; Várkonyi, Judit; Piredda, Chiara; Pelosini, Matteo; Belachew, Alem A; Subocz, Edyta; Hemminki, Kari; Rybicka-Ramos, Malwina; Giles, Graham G; Milne, Roger L; Hofmann, Jonathan N; Zaucha, Jan Maciej; Vangsted, Annette Juul; Goldschmidt, Hartmut; Rajkumar, S Vincent; Tomczak, Waldemar; Sainz, Juan; Butrym, Aleksandra; Watek, Marzena; Iskierka-Jazdzewska, Elzbieta; Buda, Gabriele; Robinson, Dennis P; Jurczyszyn, Artur; Dudzinski, Marek; Martinez-Lopez, Joaquin; Sinnwell, Jason P; Slager, Susan L; Jamroziak, Krzysztof; Reis, Rui Manuel Vieira; Weinhold, Niels; Bhatti, Parveen; Carvajal-Carmona, Luis G; Zawirska, Daria.
Afiliação
  • Macauda A; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Clay-Gilmour A; Department of Biology, University of Pisa, Pisa, Italy.
  • Hielscher T; Department of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Greenville, South Carolina.
  • Hildebrandt MAT; Division of Biostatistics, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Kruszewski M; Department of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Orlowski RZ; Department of Hematology University Hospital Bydgoszcz, Bydgoszcz, Poland.
  • Kumar SK; Department of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ziv E; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
  • Orciuolo E; Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
  • Brown EE; Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
  • Försti A; Department of Pathology, School of Medicine, University of Alabama, Birmingham, Alabama.
  • Waller RG; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
  • Machiela MJ; Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Chanock SJ; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Camp NJ; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Rymko M; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Razny M; Division of Hematology and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Cozen W; Department of Haematology and Bone Marrow Transplantation, SSM im. M. Kopernika, Torun, Poland.
  • Várkonyi J; Department of Hematology, Rydygier Hospital, Cracow, Poland.
  • Piredda C; Division of Hematology/Oncology, Department of Medicine, School of Medicine, Department of Pathology, School of Medicine, Susan and Henry Samueli College of Health Sciences, Chao Family Comprehensive Cancer Center, University of California at Irvine, California.
  • Pelosini M; Department of Hematology and Internal Medicine, Semmelweis University, Budapest, Hungary.
  • Belachew AA; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Subocz E; Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
  • Hemminki K; Department of Lymphoma - Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rybicka-Ramos M; Department of Hematology, Military Institute of Medicine, Warsaw, Poland.
  • Giles GG; Biomedical Center, Faculty of Medicine, Charles University in Pilsen, Pilsen, Czech Republic.
  • Milne RL; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hofmann JN; Department of Hematology Specialist Hospital No. 1 in Bytom, Bytom, Poland.
  • Zaucha JM; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Vangsted AJ; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Goldschmidt H; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Rajkumar SV; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Tomczak W; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Sainz J; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Butrym A; Division of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
  • Watek M; Department of Hematology and Transplantology, Medical Univeristy of Gdansk, Gdansk, Poland.
  • Iskierka-Jazdzewska E; Department of Haematology, Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
  • Buda G; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
  • Robinson DP; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
  • Jurczyszyn A; Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland.
  • Dudzinski M; Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada/Andalusian Regional Government, Granada, Spain.
  • Martinez-Lopez J; Hematology department, Virgen de las Nieves University Hospital, Granada, Spain.
  • Sinnwell JP; Department of Internal and Occupational Diseases, Medical University Wroclaw, Wroclaw, Poland.
  • Slager SL; Hematology Clinic, Holycross Cancer Center, Kielce, Poland.
  • Jamroziak K; Department of Hematology, Medical University of Lodz, Lodz, Poland.
  • Reis RMV; Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy.
  • Weinhold N; Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
  • Bhatti P; Plasma Cell Dyscrasias Center, Department of Hematology, Faculty of Medicine, Jagiellonian University, Kraków, Poland.
  • Carvajal-Carmona LG; Department of Hematology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszów, Rzeszów, Poland.
  • Zawirska D; Servicio de Hematología Centro de Actividades Ambulatorias, Madrid, Spain.
Cancer Epidemiol Biomarkers Prev ; 31(9): 1863-1866, 2022 09 02.
Article em En | MEDLINE | ID: mdl-35700034
BACKGROUND: Genome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have also been associated with patient survival. METHODS: We explored the possible association of all the known risk variants and their polygenic risk score (PRS) with multiple myeloma overall survival (OS) in multiple populations of EA [the International Multiple Myeloma rESEarch (IMMEnSE) consortium, the International Lymphoma Epidemiology consortium, CoMMpass, and the German GWAS] for a total of 3,748 multiple myeloma cases. Cox proportional hazards regression was used to assess the association between each risk SNP with OS under the allelic and codominant models of inheritance. All analyses were adjusted for age, sex, country of origin (for IMMEnSE) or principal components (for the others) and disease stage (ISS). SNP associations were meta-analyzed. RESULTS: SNP associations were meta-analyzed. From the meta-analysis, two multiple myeloma risk SNPs were associated with OS (P < 0.05), specifically POT1-AS1-rs2170352 [HR = 1.37; 95% confidence interval (CI) = 1.09-1.73; P = 0.007] and TNFRSF13B-rs4273077 (HR = 1.19; 95% CI = 1.01-1.41; P = 0.04). The association between the combined 24 SNP MM-PRS and OS, however, was not significant. CONCLUSIONS: Overall, our results did not support an association between the majority of multiple myeloma risk SNPs and OS. IMPACT: This is the first study to investigate the association between multiple myeloma PRS and OS in multiple myeloma.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estudo de Associação Genômica Ampla / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estudo de Associação Genômica Ampla / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Ano de publicação: 2022 Tipo de documento: Article